Published in Antioxid Redox Signal on May 01, 2009
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood (2014) 1.60
Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res (2009) 1.15
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS One (2012) 0.99
Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One (2011) 0.93
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. Int J Cell Biol (2010) 0.93
Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Mol Pharmacol (2012) 0.89
The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies. Free Radic Biol Med (2013) 0.81
Azacytidine induces necrosis of multiple myeloma cells through oxidative stress. Proteome Sci (2013) 0.78
Redox regulation of Janus kinase: The elephant in the room. JAKSTAT (2013) 0.77
Reactive oxygen species regulate nucleostemin oligomerization and protein degradation. J Biol Chem (2011) 0.77
Oxidative stress induces monocyte necrosis with enrichment of cell-bound albumin and overexpression of endoplasmic reticulum and mitochondrial chaperones. PLoS One (2013) 0.76
RedOx status, proteasome and APEH: insights into anticancer mechanisms of t10,c12-conjugated linoleic acid isomer on A375 melanoma cells. PLoS One (2013) 0.76
Proteomic analysis of gossypol induces necrosis in multiple myeloma cells. Biomed Res Int (2014) 0.75
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A (2000) 3.69
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res (2008) 3.58
Oxygen radicals and signaling. Curr Opin Cell Biol (1998) 3.33
Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol (2004) 3.29
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol (2001) 3.03
Mitochondrial DNA in human malignancy. Mutat Res (2001) 2.87
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood (2005) 2.82
Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem (2003) 2.80
Apoptosis-based therapies for hematologic malignancies. Blood (2005) 2.77
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans (2007) 2.70
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A (2002) 2.69
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res (2008) 2.61
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem (2006) 2.59
Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ (2006) 2.56
Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res (2003) 2.43
Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol (2001) 2.43
The thioredoxin system in cancer. Semin Cancer Biol (2006) 2.42
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res (2003) 2.30
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res (2004) 2.23
The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle. Cell Death Differ (2005) 2.22
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat (2008) 2.13
The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr (2007) 2.07
Targeting mitochondria. Acc Chem Res (2008) 2.03
Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs (2005) 2.03
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem (2000) 1.98
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs (2007) 1.95
BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med (1999) 1.95
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood (2007) 1.86
Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood (2008) 1.85
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res (2006) 1.85
A proteasome for all occasions. FEBS Lett (2007) 1.84
Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J (1998) 1.82
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood (2004) 1.81
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood (2008) 1.80
Role of mitochondria in toxic oxidative stress. Mol Interv (2005) 1.76
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res (2003) 1.70
Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell (1999) 1.58
LSD1: oxidative chemistry for multifaceted functions in chromatin regulation. Trends Biochem Sci (2008) 1.54
Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther (2007) 1.50
Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res (2004) 1.49
Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res (1990) 1.48
The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med (2008) 1.46
Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat (2004) 1.42
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia (2004) 1.38
BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat (2007) 1.33
Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol (2006) 1.31
The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs (2008) 1.31
SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis (2007) 1.30
Peroxynitrite increases the degradation of aconitase and other cellular proteins by proteasome. J Biol Chem (1998) 1.28
Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta (1995) 1.26
A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. Mol Cancer Ther (2007) 1.26
A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer (2006) 1.25
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood (2005) 1.23
Modulation of mitochondrial membrane permeability in pathogenesis, autophagy and control of metabolism. J Gastroenterol Hepatol (2007) 1.19
The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw (2007) 1.14
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg (2004) 1.13
An endogenous electrophile that modulates the regulatory mechanism of protein turnover: inhibitory effects of 15-deoxy-Delta 12,14-prostaglandin J2 on proteasome. Biochemistry (2003) 1.13
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol (2007) 1.11
The antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the degradation of p38 alpha MAPK isoform. J Immunol (2006) 1.10
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem (2006) 1.10
Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood (2003) 1.10
Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets (2008) 1.10
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther (2006) 1.09
Reactive species: a cell damaging rout assisting to chemical carcinogens. Cancer Lett (2008) 1.07
Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1. Cancer Chemother Pharmacol (2006) 1.06
Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood (2004) 1.06
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood (2002) 1.05
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol (2008) 1.05
Molecular shredders: how proteasomes fulfill their role. Curr Opin Struct Biol (2003) 1.04
Histone deacetylase inhibitors--turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases. Appl Microbiol Biotechnol (2007) 1.03
Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol (2008) 1.02
Programmed death as a therapeutic target to reduce myocardial infarction. Trends Pharmacol Sci (2007) 1.02
The "pro-apoptotic genies" get out of mitochondria: oxidative lipidomics and redox activity of cytochrome c/cardiolipin complexes. Chem Biol Interact (2006) 1.01
Redox mechanisms of cytoprotection by Bcl-2. Antioxid Redox Signal (2005) 1.01
Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen-dependent mechanism. FEBS Lett (2003) 1.01
Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis. J Neurochem (2005) 0.99
The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J Cell Biol (1991) 0.97
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res (1985) 0.97
DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol Cancer Res (2008) 0.96
Role of oxidative stress from mitochondria on aging and cancer. Cornea (2007) 0.96
Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leuk Res (2007) 0.96
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk Res (2006) 0.95
Redox aspects of Bcl-2 function. Antioxid Redox Signal (2000) 0.95
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs (2008) 0.94
Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem (2007) 0.94
Bcl-xL overexpression attenuates glutathione depletion in FL5.12 cells following interleukin-3 withdrawal. Biochem J (1997) 0.94
Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene (2004) 0.94
Bortezomib in mantle cell lymphoma. Future Oncol (2008) 0.94
Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res (2005) 0.93